Strategic partners Position Prodeon Medical as a partner for research institutions and clinical trial networks given their investigational status of the Urocross Expander System and PUR E procedure, highlighting opportunities to supply trial support, regulatory consulting, and potential future commercialization collaborations.

Clinical momentum Leverage recent AUA 2026 abstracts and attendance to open doors with urology departments and hospital systems seeking access to new BPH treatment modalities, offering training, education programs, and adoption playbooks to accelerate clinical acceptance.

Regulatory readiness Emphasize ISO 13485 certification and cloud-based data infrastructure as signals of quality management and data integrity, offering services around regulatory strategy, quality systems optimization, and post-market surveillance for future product launches.

Emerging market fit Target mid-size medical device distributors and regional hospitals focused on urology who are seeking innovative, less invasive BPH solutions, presenting a compelling case for early access programs, trial expansion, and regional training initiatives.

Commercial readiness Highlight the company’s revenue scale and footprint to frame a staged go-to-market plan, including channel partner development, clinical education grants, and payer engagement strategies to support scalable commercialization once the investigational program advances.